Position in VRTX
as of Mar 31, 2026
· filed May 5, 2026
Position Value
$2,024,165
+$2,024,165 QoQ
Shares Held
4,533
Ownership
0.002%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2021
2 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Derivatives in VRTX
reported options exposure · as of Sep 30, 2021CallValue
$4,317,082
CallShares
23,800
PutValue
$3,319,437
PutShares
18,300
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026IMC-Chicago, LLC holds $52,313,144 across 39 Biotechnology names. VRTX ranks #6 (3.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CPRX |
Catalyst Pharmaceuticals, Inc.
|
563,670 | $13,956,469 | |
| 2 | ABVX |
Abivax S.A.
|
106,143 | $11,819,023 | |
| 3 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
7,795 | $4,080,448 | |
| 4 | BNTX |
BioNTech SE
|
27,571 | $2,450,510 | |
| 5 | APLS |
Apellis Pharmaceuticals, Inc.
|
59,232 | $2,382,903 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
This page
|
4,533 | $2,024,165 | |
| 7 | AXSM |
Axsome Therapeutics, Inc.
|
7,847 | $1,326,299 | |
| 8 | ARGX |
Argenx SE
|
1,747 | $1,275,746 |
All Filings in VRTX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,024,165 | 4,533 | Shares | Sole | 2026-05-05 | |
| 2021-09-30 | $3,319,437 | 18,300 | Put | Sole | 2021-11-05 | |
| 2021-09-30 | $4,317,082 | 23,800 | Call | Sole | 2021-11-05 | |
| No filing history on record for this holder in this stock. | ||||||